Onpattro Market 2026 advancing RNA-based therapeutics

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Onpattro Market At The End Of The 2026–2030 Forecast Period?

The historic period’s growth can be attributed to progress in the field of RNA-based medication creation, a rise in the identification of hATTR amyloidosis cases, official authorizations for therapies that silence genes, more numerous specialized facilities for infusions, and the confirmed effectiveness of patisiran through clinical studies.

The projected growth throughout the forecast period is attributable to the expanding use of next-generation RNA therapeutics, an increase in investments within rare disease pipelines, a heightened emphasis on personalized medicine, the development of alternative subcutaneous delivery methods, and the rising adoption of genetic screening programs. Furthermore, significant trends observed during this period include the increasing acceptance of RNA interference therapies, a greater focus on the treatment of rare genetic diseases, the expansion of precision gene silencing approaches, improved clinical outcomes in amyloidosis care, and the growing integration of advanced infusion therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20169&type=smp

What Drivers Are Shaping The Future Growth Of The Onpattro Market?

The increasing occurrence of hereditary transthyretin-mediated amyloidosis is anticipated to drive expansion in the onpattro market moving ahead. Hereditary transthyretin-mediated amyloidosis, known as hATTR, constitutes an uncommon genetic condition in which abnormal TTR proteins accumulate as detrimental deposits, impacting both the nervous system and the heart. This growing prevalence of hereditary transthyretin-mediated amyloidosis stems from improved diagnostic methods, widespread genetic testing, and heightened public awareness, leading to the identification of a greater number of cases. Onpattro serves as a treatment for hereditary transthyretin-mediated amyloidosis by suppressing the transthyretin (TTR) gene, thereby diminishing amyloid protein formation and safeguarding against organ harm. For example, data from February 2024, published by Verywell Health, a US-based health information platform, indicates that globally, hereditary transthyretin-mediated amyloidosis impacts between 5,500–38,500 individuals. Within the U.S., estimates for hereditary transthyretin-mediated amyloidosis with polyneuropathy range from 104 to 3,847 cases, underscoring substantial underdiagnosis. Consequently, the increasing prevalence of hereditary transthyretin-mediated amyloidosis is a key factor propelling the expansion of the onpattro market.

What Segment Types Make Up The Onpattro Market?

The onpattro market covered in this report is segmented –

1) By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin Amyloidosis, Other Transthyretin-Related Amyloidoses

2) By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies

3) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers

Which Market Trends Are Creating New Opportunities In The Onpattro Market?

A significant trend in the onpattro market revolves around expanding the drug’s indications through supplemental drug applications, aiming to maximize its market potential and address a broader array of patient needs. Supplemental drug applications typically seek to extend a drug’s approved uses, such as targeting new indications, populations, or formulations, to broaden its therapeutic reach and market potential. For instance, in February 2023, Alnylam Pharmaceuticals, a US-based pharmaceutical company, announced the acceptance of a Supplemental New Drug Application (sNDA) for ONPATTRO (patisiran). This treatment is designed to target cardiomyopathy associated with transthyretin amyloidosis (ATTR). ONPATTRO functions as an RNA interference (RNAi) therapeutic specifically engineered to target the transthyretin (TTR) protein, which can accumulate abnormally in patients with ATTR amyloidosis, leading to severe complications like cardiomyopathy. The drug received its initial approval in 2018 for the treatment of polyneuropathy related to hereditary ATTR amyloidosis. The recent sNDA submission was founded on results from the Phase III APOLLO-B study, which demonstrated that patisiran significantly improved functional capacity and quality of life in patients with cardiomyopathy when compared to a placebo.

Who Are The Key Players Driving Competition In The Onpattro Market?

Major companies operating in the onpattro market are Alnylam Pharmaceuticals Inc.

Read the full onpattro market report here:

https://www.thebusinessresearchcompany.com/report/onpattro-global-market-report

Which Geographic Regions Are Influencing Demand In The Onpattro Market?

North America was the largest region in the onpattro market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onpattro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Onpattro Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20169&type=smp

Browse Through More Reports Similar to the Global Onpattro Market 2026, By The Business Research Company

Online Insurance Market Report 2026

https://www.thebusinessresearchcompany.com/report/online-insurance-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

On Demand Transportation Market Report 2026

https://www.thebusinessresearchcompany.com/report/on-demand-transportation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795